Delta-8 THC
Delta-8-Tetrahydrocannabinol
Delta-8-THC is a structural isomer of Delta-9-THC that occurs naturally in cannabis at very low concentrations (<1%). Most commercial Delta-8 products are synthesized from CBD via chemical isomerization. It produces milder psychoactive effects than Delta-9-THC and has demonstrated anti-nausea activity, but safety concerns about synthesis byproducts are significant.
Mildly psychoactive — approximately 50–66% the potency of Delta-9-THC. Produces euphoria, relaxation, and altered perception at typical doses. Higher doses can produce anxiety and impairment comparable to Delta-9-THC.
Quick Facts
- Molecular Formula
- C₂₁H₃₀O₂
- Molecular Weight
- 314.46 g/mol
- Boiling Point
- 175–178°C (347–352°F)
- Legal Status (U.S.)
- Federally contested
- Research Status
- Very limited clinical research
About Delta-8 THC
Delta-8-tetrahydrocannabinol (Δ8-THC) differs from the more familiar Delta-9-THC (Δ9-THC) only in the position of a double bond on the cyclohexene ring — at the 8th carbon rather than the 9th. This seemingly minor structural difference produces meaningful pharmacological differences: Delta-8 binds CB1 receptors with approximately 50–66% of the potency of Delta-9-THC, resulting in milder psychoactive effects that users often describe as clearer and less anxiety-provoking.
Delta-8-THC occurs naturally in cannabis at concentrations typically below 1% — too low for practical extraction. The commercial Delta-8 market that emerged after the 2018 Farm Bill is almost entirely based on chemical synthesis from CBD (hemp-derived) via acid-catalyzed isomerization. This process raises significant safety concerns: the reaction can produce numerous byproducts including Delta-9-THC, Delta-10-THC, Delta-4-THC, and various unknown reaction products. A 2021 U.S. Cannabis Council analysis found that 100% of tested commercial Delta-8 products contained detectable Delta-9-THC, and many contained potentially harmful synthesis byproducts including heavy metals from catalysts.
The most robust clinical evidence for Delta-8-THC comes from a 1995 study by Abrahamov et al. in children with cancer undergoing chemotherapy. All 8 children achieved complete prevention of vomiting with Delta-8-THC at doses of 18mg/m², with minimal psychoactive side effects — a remarkable finding that has not been replicated in larger trials.
The regulatory landscape is rapidly evolving. The DEA's 2020 Interim Final Rule stated that synthetically derived tetrahydrocannabinols remain Schedule I regardless of source. Multiple states have banned Delta-8 products. The FDA has issued warnings about Delta-8 products and received thousands of adverse event reports. As of 2024, the legal status of Delta-8 varies by state and remains federally contested.
Receptor Affinity
- CB1 agonist (~50–66% potency vs Δ9-THC)
- CB2 agonist
- GPR55 agonist
- TRPV1 agonist
Key Mechanisms
- CB1 partial agonism — produces psychoactive effects via the same pathway as Delta-9-THC, but with lower efficacy
- CB2 agonism — anti-inflammatory and immune-modulating effects
- GPR55 agonism — modulates pain and inflammation
- Antiemetic activity — mechanism not fully characterized, likely CB1-mediated in the dorsal vagal complex
Clinical Uses & Evidence
Graded using a modified GRADE framework. Grade A = strong evidence; B = moderate; C = preliminary.
Chemotherapy-Induced Nausea
Grade BA 1995 study in 8 pediatric oncology patients showed complete prevention of vomiting with Delta-8-THC (18mg/m²) with minimal psychoactive effects. Small sample; not replicated.
Key study: Abrahamov et al., Life Sciences, 1995
Anxiety
Grade CUser-reported lower anxiety compared to Delta-9-THC. No controlled trials. Anecdotal evidence only.
Pain
Grade CCB1/CB2 agonism provides mechanistic basis. Preclinical analgesic effects. No human RCTs specific to Delta-8.
Side Effects
Drug Interactions
Additive CNS depression via CB1 agonism
Delta-8-THC is metabolized by CYP3A4; may compete with other substrates
Transient tachycardia and blood pressure changes may counteract antihypertensive therapy
Always consult a pharmacist or physician before combining cannabis with prescription medications. This list is not exhaustive.
Dosing Notes
No established therapeutic dosing. Commercial products vary widely in potency and purity. The 1995 pediatric study used 18mg/m² — not translatable to consumer products. Safety of commercial Delta-8 products is uncertain due to synthesis byproducts. Start with very low doses if used. Avoid products without third-party COA testing from accredited labs. Not recommended for individuals with cardiovascular conditions, psychiatric history, or those taking CNS medications.
Dosing information is for educational purposes only. Consult a licensed healthcare provider for personalized guidance.
Legal Status
Federally contested. DEA's 2020 Interim Final Rule classifies synthetically derived THC isomers as Schedule I. Multiple states have explicitly banned Delta-8 (including Colorado, New York, Oregon, and others). Some states permit it under hemp regulations. Legal status changes frequently — verify current state law. FDA has issued consumer warnings about Delta-8 products.
Key Sources
- An efficient new cannabinoid antiemetic in pediatric oncology. Life Sciences, 1995.
- Delta-8-THC: a review of the literature. Cannabis and Cannabinoid Research, 2022.
- Contaminants in illicit drugs and novel psychoactive substances: a review. Drug Testing and Analysis, 2021.